Navigation Links
Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
Date:6/27/2008

xis' quality of science and productivity," said Paolo Poletti, MD, senior vice president of the Oncology Medicines Development Center at GSK.

"The GSK collaboration was critical to the development of Exelixis' world- class discovery group and our rapidly expanding clinical development group. Today, we have a pipeline of 11 compounds in clinical development, including XL184, which begins a phase 3 trial this summer," said George A. Scangos, president and chief executive officer of Exelixis. "This collaboration has been successful in that both companies have been able to share in the output of our discovery and development efforts and will be able to take forward multiple promising compounds with significant commercial potential in oncology. With the successful completion of the collaboration, we will have clarity regarding the exclusivity obligations under the GSK collaboration and ownership of the compounds in our pipeline."

To date, Exelixis has received approximately $235 million from GSK, which includes $150 million in upfront, milestone, and R&D support payments, and $85 million through a loan facility. Additionally, if GSK selects a second compound for further development, Exelixis will be entitled to receive an additional milestone payment of either $55 million or $27.5 million. The milestone will be due after the selected compound achieves proof-of-concept and will be creditable by GSK against amounts outstanding under the loan facility. Exelixis is eligible for development milestones and royalties on compounds selected for development and commercialization by GSK, which include XL880 and potentially one additional compound if GSK exercises its second development election. Exelixis will pay GSK a low, single-digit royalty on certain "Refused Candidates" that GSK elected not to choose with its development election which Exelixis thereafter successfully commercializes.

Background on Exelixis-GSK Collaboration

In October 2002, Exelixi
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... -- Kalorama Information says that PCR is demonstrating its ... the United States and is the dominant ... the FDA,s Emergency Use Authorization (EUA) to authorize the emergency ... of the Ebola virus was an indication that the ... IVD industry and its biennial survey on diagnostics markets ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Inc.,announced today that it has been awarded a ... Research (SBIR) grant, entitled,"Long-Acting Beta Interferon for Multiple ... Stroke (NINDS) of The National,Institutes of Health (NIH). ... the achievement of certain research milestones., George ...
... scientific and business development flexibility, TSX Exchange ... Resverlogix Corp.,("Resverlogix") (TSX:RVX) announced today that it has ... USD$17.3 million debenture., Donald McCaffrey, President and ... volatile and challenging for companies,around the globe. This ...
... begin after markets close at 2:00 p.m. PT ... ... MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today ... 2008 after the market closes on Monday, October 27, 2008., A ...
Cached Biology Technology:Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2Resverlogix Eliminates Sixty Percent of Remaining Debt 2Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2
(Date:10/30/2014)... 29, 2014  Securus Technologies, a leading ... solutions for public safety, investigation, corrections and ... exciting enhancements to its THREADS™ product, which ... actionable intelligence and focused leads for investigators. ... technological innovation through identifying and delivering solutions ...
(Date:10/29/2014)... 2014, Beaverton, OR) New research presented at ... Conference in Houston, TX showed for the first ... infection in women using a readily available nutritional ... presented by Dr. Judith A. Smith, Pharm.D., associate ... Reproductive Sciences at The University of Texas Health ...
(Date:10/29/2014)... An overwhelming number of chemicals from household and industrial ... in our bodies. But for most of them, scientists ... Now they,ve taken the first step toward doing that ... most. Their new method is published in the ACS ... F. Wambaugh and colleagues note that the risks to ...
Breaking Biology News(10 mins):Securus Technologies Adds Advanced Features to Its Industry-Leading Investigative Analytics Product 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2
... of New South Wales have cautioned that more ... to the disinfecting properties of silver nano-particles, increasingly ... nanosilver has effective antimicrobial properties against certain pathogens, ... harmful organisms to rapidly adapt and flourish, a ...
... 8 May 2013 (Geneva, Switzerland) - Strategies for pursuing ... at higher CD4 counts and innovative models for HIV ... programme announced today. , "Functional cures" and the benefits ... this year and the IAS 20I3 conference, the worlds ...
... York City,s Central Park to Golden Gate Park in San ... of carbon, an environmental service with an estimated value of ... Annual net carbon uptake by these trees is ... benefit. In the study published recently in the journal ...
Cached Biology News:Bacteria adapt and evade nanosilver's sting -- new study 2IAS 2013 conference program live online 2IAS 2013 conference program live online 3US urban trees store carbon, provide billions in economic value 2US urban trees store carbon, provide billions in economic value 3US urban trees store carbon, provide billions in economic value 4US urban trees store carbon, provide billions in economic value 5US urban trees store carbon, provide billions in economic value 6
... Arrays can be used to test the ... and sera that are commonly used as ... contains spots for 21 different protein preparations ... antibody crossreactivity and species specificity, QC of ...
... the experimental process of determining the nucleotide ... DNA Sequencing is based on Sangers enzymatic ... allows cycle sequencing reactions. The resulting fluorescent ... capillary instrument controlled by a computer and ...
... On-Demand Cytometry The Guava EasyCyte ... laser based multiparameter cytometer with built-in 96-well ... can screen plates of cells and compounds ... manipulating multiple tubes or having the carryover ...
... and finishing services are tailored to ... large-scale 5' screening or full length ... experience with large-scale genome projects and ... ideal cDNA outsourcing solution. In addition, ...
Biology Products: